Brief: Predicted Therapeutic Range Dose Levels Reached In Ator-1017 Phase I

Alligator Bioscience AB

27/10/2020 13:03

Oct 27 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * PREDICTED THERAPEUTIC RANGE DOSE LEVELS REACHED IN ATOR-1017 PHASE I
    * ALLIGATOR BIOSCIENCE AB - ADDITIONAL POSITIVE INTERIM SAFETY DATA FROM ITS ONGOING
CLINICAL
PHASE I STUDY OF DRUG CANDIDATE ATOR-1017
    * ALLIGATOR BIOSCIENCE AB - MAJORITY OF OBSERVED DRUG RELATED ADVERSE EVENTS HAVE BEEN MILD
OR
MODERATE (GRADE 1 OR 2) AND THERE ARE INDICATIONS THAT ATOR-1017 ACTIVATES IMMUNE SYSTEM OF
PATIENTS.
    * ALLIGATOR BIOSCIENCE AB - PHASE I STUDY IS PLANNED TO READ OUT IN H1 2021

Source text for Eikon:  ID:nWkr9gNPvH 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))